DE69637805D1 - Nukleinsäure liganden die dna-polymerase binden und inhibieren - Google Patents

Nukleinsäure liganden die dna-polymerase binden und inhibieren

Info

Publication number
DE69637805D1
DE69637805D1 DE69637805T DE69637805T DE69637805D1 DE 69637805 D1 DE69637805 D1 DE 69637805D1 DE 69637805 T DE69637805 T DE 69637805T DE 69637805 T DE69637805 T DE 69637805T DE 69637805 D1 DE69637805 D1 DE 69637805D1
Authority
DE
Germany
Prior art keywords
nucleic acid
dna polymerase
acid ligands
inhibiting dna
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69637805T
Other languages
English (en)
Inventor
Larry Gold
Sumedha Jayasena
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gilead Sciences Inc
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/484,557 external-priority patent/US5693502A/en
Priority claimed from US08/487,720 external-priority patent/US5874557A/en
Priority claimed from US08/487,426 external-priority patent/US5763173A/en
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Application granted granted Critical
Publication of DE69637805D1 publication Critical patent/DE69637805D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6848—Nucleic acid amplification reactions characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
DE69637805T 1995-06-07 1996-06-05 Nukleinsäure liganden die dna-polymerase binden und inhibieren Expired - Lifetime DE69637805D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/484,557 US5693502A (en) 1990-06-11 1995-06-07 Nucleic acid ligand inhibitors to DNA polymerases
US08/487,720 US5874557A (en) 1990-06-11 1995-06-07 Nucleic acid ligand inhibitors to DNA polymerases
US08/487,426 US5763173A (en) 1990-06-11 1995-06-07 Nucleic acid ligand inhibitors to DNA polymerases
PCT/US1996/009451 WO1996041010A1 (en) 1995-06-07 1996-06-05 Nucleic acid ligands that bind to and inhibit dna polymerases

Publications (1)

Publication Number Publication Date
DE69637805D1 true DE69637805D1 (de) 2009-02-26

Family

ID=27413687

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69637805T Expired - Lifetime DE69637805D1 (de) 1995-06-07 1996-06-05 Nukleinsäure liganden die dna-polymerase binden und inhibieren
DE69638318T Expired - Lifetime DE69638318D1 (de) 1995-06-07 1996-06-05 Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69638318T Expired - Lifetime DE69638318D1 (de) 1995-06-07 1996-06-05 Nukleinsäureliganden, die an DNA-Polymerasen binden und diese inhibieren

Country Status (11)

Country Link
US (1) US6020130A (de)
EP (2) EP0833944B1 (de)
JP (2) JP4335975B2 (de)
AT (2) ATE420202T1 (de)
AU (1) AU726844B2 (de)
CA (1) CA2223078C (de)
DE (2) DE69637805D1 (de)
DK (2) DK2080813T3 (de)
ES (1) ES2321243T3 (de)
PT (1) PT833944E (de)
WO (1) WO1996041010A1 (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970002255B1 (ko) * 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US20040132067A1 (en) * 1990-06-11 2004-07-08 Somalogic, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US20060084797A1 (en) * 1990-06-11 2006-04-20 Gilead Sciences, Inc. High affinity TGFbeta nucleic acid ligands and inhibitors
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US6458539B1 (en) * 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US6183967B1 (en) * 1995-06-07 2001-02-06 Nexstar Pharmaceuticals Nucleic acid ligand inhibitors to DNA polymerases
US7070925B1 (en) 1996-07-16 2006-07-04 Gen-Probe Incorporated Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
CA2260749A1 (en) * 1996-07-16 1998-01-22 Gen-Probe Incorporated Methods for detecting rna analytes using modified probes
US6426335B1 (en) * 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP1100972B1 (de) * 1998-07-31 2006-06-14 Gen-Probe Incorporated Reversibel inhibierende sonden
EP1002875A1 (de) * 1998-11-17 2000-05-24 Mira Diagnostica GmbH Oligonucleotid Inhibitor von thermostabilen Polymerasen
EP1175501A4 (de) * 1999-05-12 2002-11-27 Invitrogen Corp Zusammensetzungen und verfahren zur erhöhung der empfindlichkeit und spezifität der nukleinsäuresynthese
EP1178954A1 (de) * 1999-05-12 2002-02-13 President And Fellows Of Harvard College Auf der struktur basierendes verfahren zur entwicklung von inhibitoren der prozessiven proteinfaktor wechselwirkungen
DE60029225T2 (de) * 1999-07-02 2007-07-05 Invitrogen Corp., Carlsbad Zusammensetzungen und verfahren zu höhere empfindlichkeit und spezifität von nukleinsäuresynthese
US6830902B1 (en) 1999-07-02 2004-12-14 Invitrogen Corporation Compositions and methods for enhanced sensitivity and specificity of nucleic acid synthesis
US6214557B1 (en) * 2000-06-06 2001-04-10 Washington University Cold sensitive mutant DNA polymerases
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
EP1326892A2 (de) 2000-10-12 2003-07-16 University of Rochester Zusammensetzungen die die proliferation von krebszellen hemmen
IL159053A0 (en) 2001-05-25 2004-05-12 Univ Duke Modulators of pharmacological agents
US6667165B2 (en) 2001-11-13 2003-12-23 Eppendorf Ag Method and compositions for reversible inhibition of thermostable polymerases
AU2003209030B2 (en) 2002-02-06 2009-02-05 Stasys Technologies, Inc. Anti-infarction molecules
AU2003253580A1 (en) * 2002-02-26 2003-11-17 University Of Minnesota Variants of nedd4l associated with hypertension and viral budding
EP1552002A4 (de) * 2002-06-18 2006-02-08 Archemix Corp Aptamer-toxinmoleküle sowie verfahren zu deren verwendung
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
EP1543158B1 (de) * 2002-07-25 2011-07-13 Archemix Corp. Regulierte aptamer-therapeutika
CA2495478A1 (en) 2002-08-05 2004-02-12 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
US9303262B2 (en) * 2002-09-17 2016-04-05 Archemix Llc Methods for identifying aptamer regulators
US20050124565A1 (en) * 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US10100316B2 (en) * 2002-11-21 2018-10-16 Archemix Llc Aptamers comprising CPG motifs
EP1581548A4 (de) * 2002-11-21 2008-04-23 Archemix Corp Therapeutika mit multivalentem aptamer mit verbesserten pharmacodynamischen eigenschaften und verfahren zu deren herstellung und anwendung
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US20050037394A1 (en) * 2002-12-03 2005-02-17 Keefe Anthony D. Method for in vitro selection of 2'-substituted nucleic acids
AU2003297682A1 (en) * 2002-12-03 2004-06-23 Archemix Corporation Method for in vitro selection of 2'-substituted nucleic acids
CA2521127C (en) 2003-04-01 2014-05-27 Eragen Biosciences, Inc. Polymerase inhibitor and method of using same
US20050250106A1 (en) * 2003-04-24 2005-11-10 David Epstein Gene knock-down by intracellular expression of aptamers
ATE418621T1 (de) * 2003-04-24 2009-01-15 Afshin Ahmadian Verfahren zur detektion allelspezifischer mutationen
US7727969B2 (en) * 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US20050112585A1 (en) * 2003-11-21 2005-05-26 Dominic Zichi Method for adjusting the quantification range of individual analytes in a multiplexed assay
TR201808488T4 (tr) 2004-02-12 2018-07-23 Archemix Llc Komplemana bağlı bozuklukların tedavisinde yararlı aptamer terapötikleri.
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
RU2006135119A (ru) * 2004-03-05 2008-04-10 Аркемикс Корп. (Us) Аптамеры к семейству цитокинов il-12 человека и их применение в качестве лекарственных средств для аутоиммунных заболеваний
US20080214489A1 (en) * 2004-04-19 2008-09-04 Anthony Dominic Keefe Aptamer-mediated intracellular delivery of oligonucleotides
US7579450B2 (en) * 2004-04-26 2009-08-25 Archemix Corp. Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
KR20070101226A (ko) * 2004-09-07 2007-10-16 아케믹스 코포레이션 앱타머의 약화학
US7566701B2 (en) * 2004-09-07 2009-07-28 Archemix Corp. Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
CA2579374A1 (en) 2004-09-07 2006-03-30 Archemix Corp. Aptamers to von willebrand factor and their use as thrombotic disease therapeutics
CA2584576C (en) * 2004-10-18 2015-12-08 Brandeis University Reagents and methods for improving reproducibility and reducing mispriming in pcr amplification
EP2813581B1 (de) 2005-01-06 2018-06-27 Applied Biosystems, LLC Verwendung von Polypeptiden mit Nukleinsäurebindungsaktivität in Verfahren schneller Nukleinsäurenamplifikation
ME03528B (de) 2005-03-23 2020-04-20 Genmab As Antikörper gegen cd38 zur behandlung von multiplem myelom
US7476733B2 (en) * 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US20070059713A1 (en) 2005-09-09 2007-03-15 Lee Jun E SSB-DNA polymerase fusion proteins
WO2007041201A2 (en) * 2005-10-03 2007-04-12 Applera Corporation Compositions, methods, and kits for amplifying nucleic acids
JP2009511018A (ja) * 2005-10-06 2009-03-19 エムセラックス，エルエルシー ワクチンとしての炭疽菌芽胞糖タンパク質に関する方法及び組成物
EP2189522A1 (de) 2005-10-14 2010-05-26 MUSC Foundation For Research Development PAX2 als Ziel zur Induktion einer Immunität gegen DEFB1-vermittelte Tumore und bei der Krebstherapie
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
EP1989324B1 (de) * 2006-02-27 2011-05-18 Roche Diagnostics GmbH Pcr-heissstart durch magnesium-sequestrierung
KR101584468B1 (ko) * 2006-03-08 2016-01-13 아케믹스 엘엘씨 안질환의 치료에 유용한 보체 결합 앱타머 및 항-ｃ5 제제
RU2394915C2 (ru) * 2006-03-24 2010-07-20 Александр Борисович Четверин Бесконтактные способы обнаружения молекулярных колоний, наборы реагентов и устройство для их осуществления
DE102006015960A1 (de) 2006-04-04 2007-10-11 Qiagen Gmbh Gemisch reversibel inhibierter Enzyme
US7786294B2 (en) * 2006-06-08 2010-08-31 Saint Louis University Compositions and methods for amplification and cloning of near full-length viral genome samples
ES2376202T3 (es) * 2006-07-31 2012-03-09 Wanli Bi Amplificación de �?cidos nucleicos usando un oligonucleótido modificado reversiblemente.
US9045522B2 (en) 2006-07-31 2015-06-02 Wanli Bi Nucleic acid amplification using a reversibly modified oligonucleotide
CA2981308C (en) 2006-09-21 2020-12-22 University Of Rochester Compositions and methods related to protein displacement therapy for myotonic dystrophy
EP2104516B1 (de) 2006-11-01 2015-01-07 University of Rochester Verfahren und zusammensetzungen in zusammenhang mit der struktur und funktion von apobec3g
KR20090089462A (ko) * 2006-12-11 2009-08-21 유니버시티 오브 유타 리써치 파운데이션 병적 혈관형성 및 혈관 투과성을 치료하기 위한 조성물 및 방법
WO2008134077A1 (en) * 2007-04-30 2008-11-06 Archemix Corp. Metabolic profile directed aptamer medicinal chemistry
WO2008150495A2 (en) * 2007-06-01 2008-12-11 Archemix Corp. Vwf aptamer formulations and methods for use
ES2604764T3 (es) 2007-07-17 2017-03-09 Somalogic, Inc. Análisis de muestras de ensayo
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
EP2195340A4 (de) 2007-08-28 2011-05-11 Uab Research Foundation Synthetische apolipoprotein e-imitierende polypeptide und verwendungsverfahren
US8501912B2 (en) 2007-12-03 2013-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Filipil compositions and methods for treating cancer
US20090233993A1 (en) * 2008-03-06 2009-09-17 Burnham Institute For Medical Research Compositions and methods for inhibiting gsk3 activity and uses thereof
CA2658520C (en) 2008-03-19 2016-11-08 F. Hoffmann-La Roche Ag Nucleic acid amplification in the presence of modified randomers
EP2288922B1 (de) 2008-05-08 2016-08-17 University of Utah Research Foundation Sensorische rezeptoren für chronische müdigkeit und schmerzen und verwendungen dafür
WO2010027641A2 (en) * 2008-08-15 2010-03-11 Georgetown University Na channels, disease, and related assays and compositions
US7910720B2 (en) 2008-09-09 2011-03-22 Roche Diagnostics Operations, Inc. Polyanion for improved nucleic acid amplification
US20120070443A1 (en) 2008-12-02 2012-03-22 University Of Utah Research Foundation Pde1 as a target therapeutic in heart disease
EP2373804B1 (de) * 2008-12-05 2014-11-12 DNA Polymerase Technology, Inc. Zusammensetzungen für verbesserte genamplifikation
US9034605B2 (en) 2009-03-12 2015-05-19 Brandeis University Reagents and methods for PCR
WO2011031974A1 (en) 2009-09-10 2011-03-17 Southern Research Institute Acridine analogs in the treatment of gliomas
US8841429B2 (en) * 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
US20110207789A1 (en) 2010-02-19 2011-08-25 Ye Fang Methods related to casein kinase ii (ck2) inhibitors and the use of purinosome-disrupting ck2 inhibitors for anti-cancer therapy agents
US20110250598A1 (en) 2010-04-12 2011-10-13 Ulrike Fischer Detergent free polymerases
US10301674B2 (en) * 2010-08-20 2019-05-28 Life Technologies Corporation Polymerase assay with a FRET substrate
AU2012229067A1 (en) 2011-03-15 2013-10-31 University Of Utah Research Foundation Methods of diagnosing and treating Vascular Associated Maculopathy and symptoms thereof
JP5830286B2 (ja) * 2011-07-12 2015-12-09 アークレイ株式会社 核酸の増幅検出方法およびキット
JP5977000B2 (ja) * 2011-07-12 2016-08-24 アークレイ株式会社 核酸の増幅検出方法およびキット
JP2014531031A (ja) 2011-10-21 2014-11-20 デシマドックス， エルエルシー 小分析物の定量的検出のためのポイントオブケア免疫アッセイ
PT2855692T (pt) 2012-05-24 2019-10-25 Univ Utah Res Found Pcr extrema.
KR102264617B1 (ko) 2012-06-14 2021-06-14 라이프 테크놀로지스 코포레이션 폴리머라제 연쇄 반응 (pcr)을 위한 신규 조성물, 방법 및 키트
US9212392B2 (en) 2012-09-25 2015-12-15 Exact Sciences Corporation Normalization of polymerase activity
AU2014248886B2 (en) 2013-03-12 2019-06-27 University Of Utah Research Foundation Compositions and methods for inducing apoptosis
CN103966184A (zh) * 2014-05-06 2014-08-06 江西省科学院微生物研究所 一种实时热启动Taq酶及其制备方法
US10653747B2 (en) 2014-07-31 2020-05-19 Uab Research Foundation ApoE mimetic peptides and higher potency to clear plasma cholesterol
WO2017079636A1 (en) * 2015-11-05 2017-05-11 University Of Utah Research Foundation Extreme reverse transcription pcr
WO2017176894A1 (en) 2016-04-06 2017-10-12 Ohio State Innovation Foundation Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology
EP3471740A4 (de) 2016-06-15 2020-03-04 University of Utah Research Foundation Zusammensetzungen und verfahren zur verwendung von albuminbasierten nanomedikamenten
US11123435B2 (en) 2016-08-03 2021-09-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. TLR9 targeted therapeutics
WO2019046288A1 (en) 2017-08-31 2019-03-07 Massachusetts Institute Of Technology MULTIPLEX COMPOSITIONS AND ASSAYS FOR CHARACTERIZING ACTIVE PROTEASE AND THEIR INHIBITORS
US11198722B2 (en) 2017-10-06 2021-12-14 University Of Utah Research Foundation Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use
CN107619430B (zh) * 2017-10-17 2021-01-15 江西省科学院微生物研究所 一种热稳定的Taq酶温控亲和性配体及其制备方法、应用
GB201812192D0 (en) 2018-07-26 2018-09-12 Ttp Plc Variable temperature reactor, heater and control circuit for the same
US20220056068A1 (en) 2018-09-21 2022-02-24 King Abdullah University Of Science And Technology Ligand detection by aptamers with a built-in reporter
CN115135664A (zh) * 2020-06-22 2022-09-30 苏州新海生物科技股份有限公司 一种核酸配体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS562226A (en) 1979-06-13 1981-01-10 Nissan Motor Co Ltd Dozing drive detector
DE3546807C2 (de) * 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US5354657A (en) * 1988-01-12 1994-10-11 Boehringer Mannheim Gmbh Process for the highly specific detection of nucleic acids in solid
WO1989006694A1 (en) * 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5348010A (en) 1989-02-24 1994-09-20 Medrea, Inc., Pennsylvania Corp., Pa. Intracavity probe and interface device for MRI imaging and spectroscopy
US5503978A (en) * 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5270163A (en) * 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5580737A (en) * 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5476766A (en) * 1990-06-11 1995-12-19 Nexstar Pharmaceuticals, Inc. Ligands of thrombin
KR970002255B1 (ko) 1990-06-11 1997-02-26 넥스스타 파아마슈티컬드, 인크. 핵산 리간드
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5587468A (en) * 1990-06-11 1996-12-24 University Research Corporation High affinity nucleic acid ligands to HIV integrase
US5543293A (en) * 1990-06-11 1996-08-06 Nexstar Pharmaceuticals, Inc. DNA ligands of thrombin
US5527894A (en) * 1990-06-11 1996-06-18 Nexstar Pharmacueticals, Inc. Ligands of HIV-1 tat protein
US5567588A (en) * 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5459015A (en) * 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5472841A (en) * 1990-06-11 1995-12-05 Nexstar Pharmaceuticals, Inc. Methods for identifying nucleic acid ligands of human neutrophil elastase
CA2104698A1 (en) * 1991-02-21 1992-08-22 John J. Toole Aptamers specific for biomolecules and methods of making
US5338671A (en) * 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
US5567604A (en) * 1993-04-23 1996-10-22 Aronex Pharmaceuticals, Inc. Anti-viral guanosine-rich oligonucleotides
US20170110787A1 (en) 2015-10-14 2017-04-20 Apple Inc. Electronic Devices With Millimeter Wave Antennas And Metal Housings

Also Published As

Publication number Publication date
CA2223078A1 (en) 1996-12-19
JP2009106277A (ja) 2009-05-21
DK2080813T3 (da) 2011-03-28
EP0833944A4 (de) 1999-12-01
PT833944E (pt) 2009-04-14
CA2223078C (en) 2008-11-25
US6020130A (en) 2000-02-01
ES2321243T3 (es) 2009-06-03
DE69638318D1 (de) 2011-02-17
AU6159896A (en) 1996-12-30
JP4335975B2 (ja) 2009-09-30
ATE420202T1 (de) 2009-01-15
DK0833944T3 (da) 2009-05-11
EP0833944A1 (de) 1998-04-08
WO1996041010A1 (en) 1996-12-19
EP2080813A1 (de) 2009-07-22
ATE494394T1 (de) 2011-01-15
EP0833944B1 (de) 2009-01-07
JPH11507223A (ja) 1999-06-29
AU726844B2 (en) 2000-11-23
EP2080813B1 (de) 2011-01-05

Similar Documents

Publication Publication Date Title
DE69637805D1 (de) Nukleinsäure liganden die dna-polymerase binden und inhibieren
HK1044803A1 (en) Nucleic acid ligand inhibitors to dna polymerases
ES2169736T3 (es) Amplificacion de largas secuencias de acidos nucleicos mediante pcr.
ATE266737T1 (de) Künstliche fehlhybridisierung
DK0866071T3 (da) Modificerede primere
GB9901475D0 (en) A method of DNA sequencing
ATE427361T1 (de) Verfahren zur dna-amplifikation und - sequenzierung
BR0014182A (pt) Processos e composições para amplificação isotérmica linear de sequências polinucleotìdicas
WO1996023079A3 (en) Method for suppressing dna fragment amplification during pcr
ATE557083T1 (de) Thermostabiler oder thermoactiver dna-polymerase mit abgeschwächter 3'-5' exonukleaseaktivität
WO1996006949A3 (en) Nucleic acid hybridization assay probes targeted to mycoplasma pneumoniae nucleic acid
WO2001009347A3 (en) Archaeal replication accessory factors and methods of use
DE50115782D1 (de) THERMOSTABILE POLYMERASE AUS i THERMOCOCCUS PACIFICUS /i
DE59712270D1 (de) Verfahren zur kombination von paralleler oligonukleotidsynthese und darstellung von oligomer-chips
Stemmer Enzymatic inverse polymerase chain reaction
Rust et al. Method of detecting variant nucleic acids
WO2002050094A3 (en) Nucleic acid synthesis by primer extension on successive templates

Legal Events

Date Code Title Description
8364 No opposition during term of opposition